Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will present at the following upcoming investor conferences:

• Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021, at 1:00 p.m. ET
• BofA Securities 2021 Napa Biopharma Virtual Conference on Tuesday, June 15, 2021, at 5:30 p.m. ET

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]

You May Also Be Interested In

• Statkraft applies for licence to build new Høyanger K5 hydropower plant
• Hofseth BioCare ASA: SECOND QUARTER 2026 FINANCIAL REPORT
• WISeKey Appoints Alexander Hirsch as Group Chief Marketing Officer to Coordinate Global Marketing Across the Group